4 completed, 1 withdrawn. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
Follow Gliclazide: new trials by email Literature Review of Gliclazide trials Research Report on Gliclazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers Omeprazole, Placebo oral tablet, Gliclazide - Diabetes Mellitus, Type 2 | Phase 1 | Completed | University of Sarajevo | 15 | 2019-03-04 | 2021-08-18 |
| Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants Metformin/Gliclazide Fixed Combination, Metformin, Gliclazide - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 40 | 2018-02-16 | 2019-07-16 |
| Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations BF-Gliclazide Tablet 80mg, Diamicron 80mg Tablet - Healthy | Phase 1 | Completed | Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited | 17 | 2016-01-01 | 2016-07-25 |
| Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets Gliclazide 120 mg MR Tablets Formula A, Gliclazide 120 mg MR Tablets, Gliclazide 120 mg MR Tablets Formula B - Comparative Bioavailability | Phase 1 | Withdrawn | Disphar International B.V. | 2014-06-01 | 2016-12-02 | |
| Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers BIA 2-093, Gliclazide - Epilepsy | Phase 1 | Completed | Bial - Portela C S.A. | 20 | 2007-10-01 | 2016-05-19 |
Diabetes Mellitus, Type 2 (1) · Epilepsy (1)
Bial - Portela C S.A. (1) · Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited (1) · Disphar International B.V. (1) · Merck KGaA, Darmstadt, Germany (1) · University of Sarajevo (1)
Bosnia and Herzegovina (1) · Germany (1) · Hong Kong (1) · Jordan (1) · Portugal (1)
Aida Kulo Cesic, PhD (1) · Brian Tomlinson (1) · N. Najib, Pharm. Ph.D (1) · Risa Ozaki (1) · Tanja Dujic, PhD (1) · Vincent HL Lee (1)